Clinical trials: Metastatic Colorectal Cancer (CRC)
Metastatic Triple Negative Breast Cancer, Metastatic Colorectal Cancer
Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases
Approximately 36 DLT-evaluable subjects will be enrolled in this study. The locations of the study will be in the United States, Australia, Europe and Switzerland.
- Trial name
- NCT03256344
- Testing
- Talimogene Laherparepvec, Atezolizumab
- Where
- 17 sites in United States, Australia and 4 more
- Volunteers
- 36 people
- Sponsor
- Amgen
Colon Cancer
NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
The main objective of the trial is to document the safety of NGR-hTNF administered at low and high doses in combination with a standard oxaliplatin based regimen in patients with metastatic colorectal cancer not amenable to any…
- Trial name
- NCT00675012
- Testing
- NGR-hTNF, Oxaliplatin, capecitabine
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- AGC Biologics S.p.A.
Colorectal Cancer, Metastasis
Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab
It is a prospective, non-randomized, monocentric study. The purpose of the study is to assess the predictive value of VE-cadherin on the objective tumor response.
- Trial name
- AVECC (NCT01405430)
- Testing
- Bevacizumab + blood samples
- Where
- 2 sites in France
- Volunteers
- 63 people
- Sponsor
- Centre Leon Berard
Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
The phase II trial tests whether pembrolizumab and dendritic cell-based treatment works to shrink tumors in patients with colorectal cancer that does not respond to treatment (refractory).
- Conditions
- Metastatic Microsatellite Stable Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT05518032
- Testing
- Biopsy, Pembrolizumab, Therapeutic Autologous Dendritic Cells
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Metastatic Colorectal Cancer, KRAS G12C Mutations
A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations
To learn if the drug combination of adagrasib, cetuximab, and cemiplimab can help to control metastatic CRC with KRAS G12C mutations.
- Trial name
- NCT06412198
- Testing
- Cetuximab, Cemiplimab, Adagrasib
- Where
- 2 sites in United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Refractory Metastatic Colorectal Cancer
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority Trial
This study is an investigator-initiated, prospective, multicenter, randomized, controlled, open-label, non-inferiority trial designed to evaluate the efficacy and safety of trifluridine/tipiracil plus fruquintinib versus…
- Trial name
- NCT07261709
- Testing
- Trifluridine/tipiracil plus fruquintinib, trifluridine/tipiracil plus bevacizumab
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Pyrotinib in Combination With Trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
This clinical trial aims to evaluate the efficacy, safety of Pyrotinib in combination with trastuzumab in Treatment-refractory, HER2-positive Metastatic Colorectal Cancar.
- Trial name
- NCT03843749
- Testing
- Pyrotinib
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Changzheng Hospital
Colorectal Cancer
A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal Cancer
This is a multicenter, open-label, Phase 1 study of SC-006 given as a single agent and in combination with ABBV-181 in participants with advanced colorectal cancer (CRC), and consists of Part A (single agent SC-006 dose regimen…
- Trial name
- NCT03035279
- Testing
- SC-006, ABBV-181
- Where
- 9 sites in United States
- Volunteers
- 29 people
- Sponsor
- AbbVie
Colorectal Neoplasms, Anal, Colon, and Rectal Cancers
Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer
Current therapies for metastatic colorectal cancer only prolong life for approximately 2 years. A more innovative therapy that prolongs life significantly or even cures is needed.
- Trial name
- NCT00780988
- Testing
- Autologous tumor cell + CpG vaccine, Autologous hematopoietic and immune cell rescue (transplantation)
- Where
- United States
- Sponsor
- Stanford University
Colorectal Cancer, Metastatic Cancer
OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer
A study investigating if analysis of circulating tumor DNA (ctDNA) can guide adjuvant treatment in patients with advanced colorectal cancer (CRC)
- Trial name
- OPTIMISE (NCT04680260)
- Testing
- Standard of care, Circulating tumor DNA guided treatment approach
- Where
- 2 sites in Denmark
- Volunteers
- 350 people
- Sponsor
- Karen-Lise Garm Spindler
Metastatic Colorectal Cancer
Phase II Study to Evaluate Safety and Efficacy of Cetuximab in Combination With XELOX for 12 Weeks Followed by Maintenance Treatment With Cetuximab Plus Capecitabine as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer.
The purpose of this study is to determine confirmed objective response rate to combination therapy with cetuximab plus XELOX for 4 cycles followed by maintenance treatment with cetuximab plus capecitabine as first line treatment…
- Trial name
- NCT00531115
- Testing
- cetuximab 5mg/ml
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Lung Cancer, Lung Diseases
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
This study aims to explore the efficacy of Trop2, EpCAM-specific PET/CT imaging for noninvasive visualization of Trop2 or EpCAM expression levels in non-small cell lung cancer; and to explore the differences between novel…
- Conditions
- Lung Cancer, Lung Diseases, Lung Neoplasms, Lung Cancer Metastatic
- Trial name
- NCT07026110
- Testing
- [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Metastatic Colorectal Cancer
The Efficacy and Safety of Fruquintinib Plus FOLFIRI/FOLFOX as Second-line Treatment in Patients With RAS-mutant Metastatic Colorectal Cancer
RAS mutations are found in nearly half of colorectal cancer patients. However, there is no targeted driver gene drugs have been approved for RAS-mutated patients.
- Trial name
- NCT05634590
- Testing
- Fruquintinib, FOLFIRI, mFOLFOX6
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Hand-Foot Skin Reaction (HFSR)
ZINCLO-HAND: Zinc and Clobetasol for the Prevention of Regorafenib-Induced Hand-Foot Skin Reaction
This study aims to evaluate whether a combination of oral zinc supplementation and transdermal clobetasol cream is effective in preventing and reducing the severity of hand-foot skin reaction (HFSR) induced by regorafenib…
- Trial name
- ZINCLO-HAND (NCT06856590)
- Testing
- Zinc Supplementation, Clobetasol Propionate 0.05% Cream
- Where
- 13 sites in Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Gazi University
BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
This phase I/II trial studies the best dose and side effects of encorafenib, cetuximab, and nivolumab and how well they work together in treating patients with microsatellite stable, BRAFV600E gene mutated colorectal cancer that…
- Conditions
- BRAF NP_004324.2:p.V600E, Metastatic Colon Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma
- Trial name
- NCT04017650
- Testing
- Cetuximab, Encorafenib, Nivolumab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment
RATIONALE: Monoclonal antibodies such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00538291
- Testing
- cetuximab, capecitabine, gene expression analysis
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer, Esophageal Cancer
Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT00019513
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Metastatic Colorectal Cancer
EORTC-endorsed, Prospective European Multicenter Imaging Survey and Protocol
A prospective, multicenter imaging Delphi survey among European radiological societies for mCRC imaging standardization.
- Trial name
- NCT04656782
- Testing
- Imaging survey, Facilitation
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00006050
- Testing
- FOLFOX regimen, fluorouracil, isolated perfusion
- Where
- 3 sites in France
- Sponsor
- UNICANCER
Colorectal Neoplasms
Metastatic Colorectal Cancer Patients With Long-term Response to Regorafenib
The aim of this local NIS(Non-Interventional Study) is to determine the proportion of Belgian patients with a duration of treatment(DoT) to Stivarga of 4 months or more in relation to the total population of Belgian metastatic…
- Trial name
- COLONG (NCT03386825)
- Testing
- Regorafenib (Stivarga, BAY73-4506)
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- Bayer